scPharmaceuticals, Inc. (SCPH): Koefisien rega marang pendapatan
scPharmaceuticals Inc. (SCPH) cash flows are protected by patents for furosemide delivery systems and stringent FDA controls. The company's price-to-sales ratio clearly confirms this trend, where the value 6.00 represents the current metric. While high global growth potential is based on intellectual property, financial stability currently relies solely on the success of a single flagship product.
Rincian analitis perusahaan scPharmaceuticals Inc. (SCPH)
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi scPharmaceuticals Inc.|SCPH - Utang jangka dawa marang modal|Utang jangka cendhak marang modal scpharmaceuticals.com|SCPH - Utang perusahaan|Rasio utang marang aset resik scPharma|SCPH - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan scPharmaceuticals|Rasio cepet scpharmaceuticals.com
- data bathi bisnis lan rasio investasi:
SCPH - Bathi resik|Bathi mangsa ngarep scPharmaceuticals Inc.|SCPH - Pangali P/E|Rasio prakiraan rega marang bathi scpharmaceuticals.com|SCPH - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA scPharma|SCPH - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan scPharmaceuticals|SCPH - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan scpharmaceuticals.com|SCPH - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep scPharmaceuticals Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:scPharmaceuticals, Inc., SCPH
For scPharmaceuticals Inc. (SCPH), which monetizes home treatment for heart failure via the Furoscix system, this indicator determines the market value of each unit of generated revenue. By analyzing the P/S multiple, an investor compares market capitalization with revenue from insurance reimbursements, allowing for an assessment of the premium paid for business scaling potential and the sustainability of the valuation amid the transition of patients from inpatient to home care.
Pesaing scPharmaceuticals Inc.
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue KVUE|Koefisien rega marang pendapatan Verona Pharma PLC (VRNA)|Jyong Biotech Corp - Multiplikator P/S|Ligand Corp (LGND) - Kapitalisasi marang pendapatan|Amneal Pharmaceuticals (AMRX) - Rasio rega marang pendapatan|Rasio rega marang dodolan PRGO (perrigo.com)|ALVO (Alvotech SA) - Multiplikator P/S|LQDA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S GLPG|Multiplikator P/S ANI Pharmaceuticals Corp (ANIP)|Rasio rega marang pendapatan MannKind Corporation MNKD|Rasio kapitalisasi pasar marang pendapatan AMPH|PCRX - Rasio rega marang pendapatan|ARS Pharmaceuticals Inc (SPRY) - Kapitalisasi marang pendapatan|TBPH: Multiplikator P/S|Aquestive Corp (AQST) - Multiplikator P/S|TECX (Tectonic Therapeutic Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan tonixpharma.com (TNXP)|Multiplikator P/S SXTC|EPRX - Rega marang dodolan|BioHarvest - Kapitalisasi marang pendapatan|Multiplikator P/S Invizyne EXOZ|ORMP: Kapitalisasi marang pendapatan|Entera Bio Ltd. - Kapitalisasi marang volume dodolan|HYFT: Multiplikator P/S|ABVC - Koefisien rega marang pendapatan|CPIX (Cumberland Pharma) - Multiplikator P/S|Kapitalisasi marang pendapatan Quantum BioPharma Corp (QNTM)|Multiplikator P/S FGEN|Multiplikator P/S telomirpharma.com (TELO)|Rasio rega marang pendapatan Rani Therapeutics Holdings, Inc. RANI|Synergy CHC Corp. - Rasio rega marang pendapatan|RLYB - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Lexaria Bioscience LEXX|PULM (Pulmatrix, Inc.) - Kapitalisasi marang pendapatan|Pheton Holdings - Rasio kapitalisasi pasar marang pendapatan|APM (Aptorum Group Ltd) - Multiplikator P/S|Lyra Therapeutics Inc. (LYRA) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Impact BioMedical (IBO)|tnfpharma.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S YCBD (cbdMD)|PRFX - Kapitalisasi marang pendapatan|CYTO: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Lipella Pharmaceuticals Inc LIPO|Optinose (OPTN) - Rasio rega marang pendapatan|PIRS - Koefisien rega marang pendapatan|PROC (Procaps Group S.A.) - Multiplikator P/S|Kapitalisasi marang pendapatan petrospharma.com (PTPI)|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN: Rasio rega marang dodolan|Multiplikator P/S TFFP (TFF Pharma)
